文献速递小儿泌尿与泌尿修复肾癌与肾肿瘤

第三个AIEOP儿童肾母细胞瘤协作方案(TW2003)结果及相关思考

Results of the Third AIEOP Cooperative Protocol on Wilms Tumor (TW2003) and Related Considerations.
PubMed 文献 · J Urol · 2017-06-24

TW2003是意大利第三个儿童肾母细胞瘤前瞻性研究,纳入453例单侧肾母细胞瘤患儿,旨在提高III-IV期生存、降低I-II期非间变型治疗强度并优化风险分层。5年无事件生存率和总生存率按I、II、III、IV期分别为89.1%和97.0%、85.1%和94.0%、82.7%和90.9%、72.1%和82.5%;多变量分析仅间变型对无事件生存率(HR 2.68)和总生存率(HR 5.29)显著。

要点

  • I-IV期5年无事件生存率89.1%、85.1%、82.7%、72.1%,总生存率97.0%、94.0%、90.9%、82.5%。
  • 42%患儿接受术前化疗,初始治疗由当地医生根据立即手术风险选择。
  • 多变量分析仅间变型对无事件生存率(HR 2.68)和总生存率(HR 5.29)显著。

核心结论

  • 所达到的生存率和提出的风险分层方案为未来比较肾母细胞瘤治疗负担和患者结局提供了基础。

研究设计与样本

  • TW2003为意大利第三个儿童肾母细胞瘤前瞻性研究,招募18岁及以下原发性肾内肿瘤患儿。
  • 共报告453例单侧肾母细胞瘤患者,局部医生根据立即手术不安全或切除不完整的风险选择肾切除联合或不联合术前化疗。
  • 辅助治疗的主要决定因素为肿瘤分期和弥漫性间变,并研究纳入患者年龄、III期指定原因和IV期肺结节反应完整性的新风险分层方案。

主要发现

  • 42%患者接受了术前化疗。
  • I期5年无事件生存率89.1%(95%CI 83.6-94.9),总生存率97.0%(95%CI 93.7-100)。
  • II期(160例)5年无事件生存率85.1%(95%CI 79.6-91.1),总生存率94.0%(95%CI 90.1-98.1)。
  • III期(101例)5年无事件生存率82.7%(95%CI 75.3-90.8),总生存率90.9%(95%CI 85.0-97.1)。
  • IV期(69例)5年无事件生存率72.1%(95%CI 61.9-84.0),总生存率82.5%(95%CI 73.1-93.1)。

关键数值与推荐

  • 多变量分析仅间变型对无事件生存率显著(HR 2.68,95%CI 1.48-4.86,p=0.001;偏倚校正c-index 0.580)。
  • 多变量分析仅间变型对总生存率显著(HR 5.29,95%CI 2.52-11.12,p<0.001;偏倚校正c-index 0.697)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: TW2003, the third Italian prospective study on Wilms tumor, aimed to improve survival in patients with stage III-IV tumors, de-escalate therapy for stage I-II nonanaplastic tumors, refine the risk stratification of therapy, and develop a national infrastructure for biobanking and central pathology review. MATERIALS AND METHODS: TW2003 recruited children 18 years old or younger with primary intrarenal tumors. Local physicians chose nephrectomy with or without preoperative chemotherapy as the initial treatment based on the risk of unsafe and/or incomplete immediate surgery. The main drivers for adjuvant therapy were tumor stage and diffuse anaplasia. A new risk stratification schema was investigated, incorporating patient age, reason for stage III designation and completeness of lung nodule response in stage IV disease. RESULTS: We report on 453 patients with unilateral Wilms tumor. Preoperative chemotherapy was administered to 42% of patients. The 5-year event-free survival and overall survival rates were 89.1% (95% CI 83.6-94.9) and 97.0% (93.7-100) for stage I; 85.1% (79.6-91.1) and 94.0% (90.1-98.1) for stage II (160); 82.7% (75.3-90.8) and 90.9% (85.0-97.1) for stage III (101); and 72.1% (61.9-84.0) and 82.5% (73.1-93.1) for stage IV (69), respectively. On multivariable analysis only anaplasia was significant for event-free survival (HR 2.68, 95% CI 1.48-4.86, p=0.001; bias corrected c-index 0.580) and overall survival (HR 5.29, 95% CI 2.52-11.12, p <0.001; bias corrected c-index 0.697). CONCLUSIONS: The survival rates achieved and the proposed risk stratification schema provide a basis for future comparisons of Wilms tumor treatment burden and patient outcome.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Spreafico F, Biasoni D, Lo Vullo S, et al. Results of the Third AIEOP Cooperative Protocol on Wilms Tumor (TW2003) and Related Considerations. J Urol. 2017. PMID: 28655531. doi:10.1016/j.juro.2017.06.081

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。